Comparison of the clinical characteristics of the discovery and validation cohorts
Characteristics . | Discovery cohort . | Validation cohort . | P . |
|---|---|---|---|
| No. patients | 363 | 209 | |
| Median age ± standard deviation, y | 37.3 ± 10.5 | 34.6 ± 13.3 | .009 |
| Patient sex, no. (%) | .589 | ||
| Male | 208 (57) | 125 (60) | |
| Female | 155 (43) | 84 (40) | |
| Donor sex, no. (%) | .967 | ||
| Male | 221 (61) | 128 (61) | |
| Female | 142 (39) | 81 (39) | |
| Patient race, no. (%) | .524 | ||
| White | 320 (88) | 188 (90) | |
| Nonwhite* | 43 (12) | 21 (10) | |
| Reason for transplantation, no. (%) | .781 | ||
| Low-risk disease | 173 (48) | 97 (46) | |
| Intermediate-risk disease | 100 (27) | 63 (30) | |
| High-risk disease | 90 (25) | 49 (24) | |
| Total body irradiation, no. (%) | .535 | ||
| No | 73 (20) | 35 (17) | |
| Yes | 290 (80) | 174 (83) | |
| Pretransplantation FEV1, no. (%) | .1 | ||
| More than 80% | 330 (91) | 178 (85) | |
| 70% to 80% | 19 (5) | 22 (10) | |
| 60% to 70% | 11 (3) | 8 (4) | |
| Less than 60% | 3 (1) | 1 (< 1) | |
| GVHD no. (%) | .51 | ||
| No acute or chronic | 141 (39) | 74 (35) | |
| Acute only | 0 (0) | 0 (0) | |
| De novo chronic | 23 (6) | 12 (6) | |
| Quiescent-onset chronic | 187 (43) | 91 (43) | |
| Progressive-onset chronic | 42 (12) | 33 (16) | |
| Median follow-up time ± standard deviation, y | 3.1 ± 2.8 | 6.0 ± 4.5 | < .001 |
| Patients with significant airflow decline, no. (%) | 133 (37) | 66 (32) | .236 |
Characteristics . | Discovery cohort . | Validation cohort . | P . |
|---|---|---|---|
| No. patients | 363 | 209 | |
| Median age ± standard deviation, y | 37.3 ± 10.5 | 34.6 ± 13.3 | .009 |
| Patient sex, no. (%) | .589 | ||
| Male | 208 (57) | 125 (60) | |
| Female | 155 (43) | 84 (40) | |
| Donor sex, no. (%) | .967 | ||
| Male | 221 (61) | 128 (61) | |
| Female | 142 (39) | 81 (39) | |
| Patient race, no. (%) | .524 | ||
| White | 320 (88) | 188 (90) | |
| Nonwhite* | 43 (12) | 21 (10) | |
| Reason for transplantation, no. (%) | .781 | ||
| Low-risk disease | 173 (48) | 97 (46) | |
| Intermediate-risk disease | 100 (27) | 63 (30) | |
| High-risk disease | 90 (25) | 49 (24) | |
| Total body irradiation, no. (%) | .535 | ||
| No | 73 (20) | 35 (17) | |
| Yes | 290 (80) | 174 (83) | |
| Pretransplantation FEV1, no. (%) | .1 | ||
| More than 80% | 330 (91) | 178 (85) | |
| 70% to 80% | 19 (5) | 22 (10) | |
| 60% to 70% | 11 (3) | 8 (4) | |
| Less than 60% | 3 (1) | 1 (< 1) | |
| GVHD no. (%) | .51 | ||
| No acute or chronic | 141 (39) | 74 (35) | |
| Acute only | 0 (0) | 0 (0) | |
| De novo chronic | 23 (6) | 12 (6) | |
| Quiescent-onset chronic | 187 (43) | 91 (43) | |
| Progressive-onset chronic | 42 (12) | 33 (16) | |
| Median follow-up time ± standard deviation, y | 3.1 ± 2.8 | 6.0 ± 4.5 | < .001 |
| Patients with significant airflow decline, no. (%) | 133 (37) | 66 (32) | .236 |
FEV1 expressed as a percent of predicted normal values.
Nonwhite includes African American, Asian, Hispanic, and Native American